Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study, is to evaluate Circulating Melanoma Cell (CMC) changes in
Metastatic Melanoma (MM) patients, undergoing treatment with selective inhibitors of mutated
BRAF.